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Abstract
Introduction: The finding of antinuclear antibody (ANA) positivity in a healthy individual is usually of unknown
significance and in most cases is benign. However, a subset of such individuals is at risk for development of
autoimmune disease. We examined demographic and immunological features that are associated with ANA
positivity in clinically healthy persons to develop insights into when this marker carries risk of progression to lupus.
Methods: Biological samples from healthy individuals and patients with systemic lupus erythematosus (SLE) were
obtained from the Dallas Regional Autoimmune Disease Registry (DRADR). Measurements carried out on serum
samples included ANA, extractable nuclear antibodies (ENA) and autoantibody profiling using an array with more
than 100 specificities. Whole blood RNA samples from a subset of individuals were used to analyze gene
expression on the Illumina platform. Data were analyzed for associations of high ANA levels with demographic
features, the presence of other autoantibodies and with gene expression profiles.
Results: Overall, ANA levels are significantly higher in females than in males and this association holds in patients
with the autoimmune diseases lupus and rheumatoid arthritis (RA) as well as in healthy controls (HC). Age was not
significantly associated with ANA levels and the elevated ANA values could not be explained by higher IgG levels.
Another autoantibody, anti- cyclic citrullinated peptide (CCP), did not show gender dimorphism in rheumatoid
arthritis (RA) or healthy individuals. The autoantigen array showed significant elevations of other autoantibodies in
high ANA HCs. Some of these autoantibodies were directed to antigens in skin and others were related to
autoimmune conditions of kidney, thyroid or joints. Gene expression analyses showed a greater prevalence of
significantly upregulated genes in HCs with negative ANA values than in those with significant ANA positivity.
Genes upregulated in high ANA HCs included a celiac disease autoantigen and some components of the Type I
interferon (IFN) gene signature.
Conclusions: Risks for ANA positivity include female gender and organ-specific autoimmunity. Upregulation of
skin-specific autoantibodies may indicate that early events in the break of tolerance take place in cutaneous
structures. Some of these changes may be mediated by Type I IFN. Blood profiling for expressed autoantibodies
and genes has the potential to identify individuals at risk for development of autoimmune diseases including
lupus.
Introduction
Antinuclear antibodies (ANAs) are measurable in
approximately 25% of the population, and the preva-
lence of significantly elevated levels may be 2.5% [1].
Findings from numerous studies show remarkable con-
sistency across ethnically and racially diverse study
populations despite the use of many different methods
for ANA measurement. The persistence of this type of
autoreactivity in the human population suggests that
antinuclear antibodies may be an important component
of the normal immune response. Most individuals with
a positive ANA do not have an autoimmune disease and
most also are unlikely to develop one. This is consistent
with the fact that the prevalence of all autoimmune dis-
orders is 5 to 7% [2]. Furthermore, the disease that is
most closely linked to ANA positivity, systemic lupus
erythematosus (SLE), is relatively rare, affecting no more
than 1 to 1.5 per 1,000 persons (0.1 to 0.15%) in the
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for all practical purposes a requirement for SLE diagno-
sis, it must also be assumed that individuals who are in
preclinical disease stages are represented in the ANA
positive healthy population. Although many consulta-
tions for ANA positivity seen in rheumatology practice
are not associated with any identifiable pathology, it is
also true that if early detection of SLE is to become fea-
sible, focus on the ANA positive population will be
necessary.
We have considered the possibility that other blood
markers could be used to differentiate benign ANA
positivity from that which carries a high risk of autoim-
mune disease. These markers may include other autoan-
tibodies, since it is well-known that autoantibody
positivity increases in quantity and complexity in years
preceding a diagnosis of SLE [4]. Gene dysregulation in
peripheral blood cells has been closely associated with
SLE diagnosis and disease s t a t u s ,s oc h a n g e si ng e n e
expression may also signal a condition with enhanced
risk.
To address these questions, we studied healthy indivi-
duals and patients with autoimmune diseases who had
been enrolled in the Dallas Regional Autoimmune Dis-
ease Registry (DRADR). A subgroup of healthy controls
that were found to have high ANA levels was examined
in greater detail using autoantigen and gene expression
arrays. The findings suggest the feasibility of identifying
risk markers for development of SLE in the setting of
ANA positivity, using both demographic features and
profiling of autoantibodies and expressed genes in per-
ipheral blood.
Materials and methods
Patients and healthy controls
Samples for study were obtained from the Dallas Regio-
nal Autoimmune Disease Registry (DRADR). Individuals
are classified according to clinical diagnosis or healthy
condition at the time of enrollment into the registry.
D i s e a s ef e a t u r e sa n dt h ep r e s e n c eo fS L Ec r i t e r i aw e r e
determined by patient interview and medical record
review [5]. Blood samples were obtained for banking of
serum aliquots and whole blood samples were stored in
PaxGene tubes for later isolation of RNA. All samples
were maintained at -80°C until use. The overall study
group included 1,159 individuals from DRADR: 401
healthy controls (HC) who were negative for current or
past autoimmune disease, 116 first-degree relatives
(FDR), 294 patients with SLE, 151 patients with less
than 4 SLE criteria and considered as having incomplete
lupus (ILE), 154 with rheumatoid arthritis (RA) and 43
with other miscellaneous conditions including sclero-
derma, Sjogren’s syndrome, ankylosing spondylitis and
vasculitis. More detailed analyses were carried out on a
subset of HC individuals with high ANA values (n = 18)
and these were compared to gender- and age-matched
HC with negative ANA values (n = 16) and to SLE
patients with high ANA levels of >100 E.U. (n =1 4 ) .I n
one experiment, plasma samples from the Dallas Heart
Study population, which has been described previously
[1], were employed. All subjects gave written informed
consent for entry into the Dallas Regional Autoimmune
Disease Registry. Research carried out under the aus-
pices of this registry has been approved by the UT
Southwestern Institutional Review Board.
Antibody assays
Serum ANA levels were measured by ELISA (Inova, San
Diego, CA, USA) using the manufacturer’s suggested
cut-off of >20 units to define positive results. Other
ELISA kits were used to measure CCP antibodies
(Inova), thyroglobulin autoantibodies (Genway Biotech
Inc., San Diego, CA, USA) and total IgG (Bethyl Labora-
tories Inc., Montgomery, TX, USA). The extractable
nuclear antibody (ENA) panel for eight additional speci-
ficities was a Luminex-based multiplex assay, and posi-
tive results were as defined by the manufacturer (Inova).
Serum reactivity to a panel of approximately 101 auto-
antigens and 6 controls was measured on a slide-based
array that has been described previously (Additional
file 1) [6]. Serum samples (1 μL, diluted 1:100) were
added to each array in duplicate and autoantibodies
were detected with Cy3-labelled anti-human IgG and
Cy-5 labeled anti-human IgM simultaneously. Images
were generated for analysis and mean fluorescence
intensities (MFI) were determined as previously
described. Heat maps were generated using Cluster and
Treeview software (Michael Eisen, Berkeley CA, USA)
[7]. On the heat map, intensities higher than the row
mean are colored red, those below the mean are green
and cells with signals close to the mean are black. Gray
was used to denote missing data.
Gene expression analysis
Total RNA was prepared from 2.5 to 5.0 ml of blood
collected in Paxgene tubes that had been stored at
-80°C. Purity and concentration of the isolated RNA was
determined using Bioanalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA) and Nanodrop 1000 spec-
trophotometer (Thermo Scientific, Wilmington, DE,
USA). We used 250 ng of total RNA to generate bioti-
nylated cRNA using a TotalPrep RNA Amplification kit
(Ambion, Austin, TX, USA). The samples were applied
to Ilumina HumanWG-6 v3.0 Expression Bead Chips
(Illlumina Inc., San Diego, CA, USA) following the man-
ufacturer’s directions. The resulting array data were ana-
lyzed using Ilumina GenomeStudio software (version 3)
and statistical analyses were carried out using Partek
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USA). Heat maps were generated using the Cluster and
Treeview programs [7].
Statistical analyses
Data are presented as mean values and standard errors of
the mean. Continuous variables in experiments with
three or more groups of samples were analyzed using a
one-way ANOVA with Tukey’s multiple comparison test
for post test analysis of pairs of samples or the Kruskal-
Wallis test for data that did not fit a normal distribution.
Analyses of experimental data with two comparison
groups used an unpaired 2-tailed Student’s t-test, with
Welch’s correction for groups with unequal variances or
Mann-Whitney U for data that did not fit a normal dis-
tribution. Pearson’s correlation coefficient was used to
compare continuous variables. Discontinuous variables
were compared using Fisher’s Exact Test. Graph pad
PRISM software (version 5.0a; GraphPad Software, La
Jolla, CA, USA) was used for data analysis and graphics.
P-values <0.05 were considered significant.
Results
ANA and autoantibodies
Using the defined cut-off of >20 ELISA units (EU), 615
individuals out of the 1,159 tested were ANA positive.
For the subset of 401 HC, the average ANA was 19.5
EU and 101 individuals were in the positive range. This
rate of 25% HC positivity is very close to what we have
reported previously [1]. Healthy FDRs had a slightly
higher overall average ANA (24.4 EU) and a prevalence
of ANA positivity of 34%. These values were not signifi-
cantly different than in the HCs (P >0.07 for both). For
the overall group, ANA values were significantly higher
in females than in males (Figure 1) and no males had
values >240 EU while 3.2% of females had values in this
range (P = 0.0030). When the analysis was limited to
HC, females again showed significantly higher ANA
levels than males (21.4 vs. 15.6 EU; P = 0.033) and ANA
positivity was also more prevalent in HC females (29%)
than in HC males (17%; P = 0.014). This corresponds to
a relative risk of ANA positivity in healthy females vs.
males of 1.21 (95% confidence interval = 1.059 to
1.390). The highest ANA levels were seen almost exclu-
sively in non-Hispanic females (data not shown),
although the overall mean values for Hispanic and non-
Hispanic females were not significantly different (P =
0.7). African-American (AA) HC (n =3 2 )h a dah i g h e r
mean ANA value than non-AAs (27.47 ± 5.8 EU vs.
18.1 ± 5.8 EU), but the difference did not reach statisti-
cal significance (P = 0.064). Within each gender, AA
individuals also had higher values than non-AA indivi-
duals (females: 30.38 ± 8.12 EU vs. 20.59 ± 1.80 EU;
males 21.09 ± 5.55 EU vs. 15.17 ± 1.31 EU); these
differences were also not significant (P >0.1 for each).
H o w e v e r ,t h er e s u l t sa r eh i g h l ys u g g e s t i v eo fh i g h e r
ANA values in AA HC, and the differences might
achieve significance in a larger sample size. Patients
with SLE did not show gender differences in overall
ANA values, although the very highest ANA values
were again seen exclusively in females (Figure 1).
We compared these findings to another autoimmune
disease, RA, which is associated with the CCP autoanti-
body. While RA patients showed significantly higher
ANA levels in females than in males (Figure 2), antibo-
dies to CCP did not show gender differences in either
the control population represented by the Dallas Heart
Study or in RA patients from DRADR (Figure 2). These
findings suggest that female gender is a general risk fac-
tor for ANA but is not necessarily a correlate with other
autoimmune disease-specific antibodies.
Age was not related to ANA positivity in HCs; high
values were scattered throughout the age spectrum
(R
2 = 0.01). The high ANA levels in HC also were not
explained by overall increases in total IgG as the two
measures were not significantly correlated (R
2 =0 . 1 1 ;
P = 0.2).
To further understand high ANA levels in HC, a sub-
group analysis was done using HC subjects with ANA
values greater than 40 EU as the index group. This
value is approximately one standard deviation greater
than the overall mean ANA for HC. A total of 18 of the
401 HC, or about 4%, fit this definition of high ANA.
Two comparator groups, HC with negative ANA (ANA
values <12 EU) and SLE patients with high ANA (>100
EU) were generally matched for demographic features
including gender, race and ethnicity (Table 1). Autoanti-
bodies on the ENA panel were generally not elevated in
the high ANA HC group. Only 3 of the 18 individuals
showed positive ENA results, and in all three the lone
positive specificity was anti-chromatin.
The three study groups were then compared using the
autoantigen array for both IgG and IgM autoantibodies
(Figures 3 and 4). Two major IgM clusters showed a ten-
dency for the SLE patients to cluster together, but this
was not statistically significant (P = 0.08); the high ANA
HC individuals had a similar tendency to be in the non-
SLE cluster (P = 0.06; Figure 3). For IgG, two primary
IgG clusters were identified, and all of the SLE patients
were in one of these clusters (P = 0.009; Figure 4).
Antibodies detected on the arrays were then examined
for specificities appearing in HC that were lupus-like.
This was defined as overall mean values for a given speci-
ficity showing no difference between the high ANA HC
and SLE groups (P >0.1) while at the same time having
lower values in the low ANA HC group compared to SLE
(P <0.1). The antibodies in these groups were examined
to choose those with stepwise increases in the groups
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Page 3 of 11Figure 1 Serum ANA levels measured by ELISA in individuals enrolled in DRADR. Results are shown for all individuals, regardless of
diagnosis (top panel), for healthy control (HC) subjects only (middle panel) and for SLE patients only (bottom panel). For each set of results,
mean and SEM values are shown on the left and individual values are plotted on the right; male and female groups are compared using t-tests.
ELISA values greater than 20 units are considered positive.
FEMALE MALE
0
100
200
300
P =0 . 0 1 5 6
A
N
A
 
E
L
I
S
A
 
U
N
I
T
S
FEMALE MALE
0
100
200
300
C
C
P
 
E
L
I
S
A
 
U
N
I
T
S
FEMALE MALE
0
100
200
300
C
C
P
 
E
L
I
S
A
 
U
N
I
T
S
Figure 2 Serum antibody levels measured by ELISA in RA patients and community-derived control subjects. ANA levels in RA patients
from DRADR (L panel) were significantly higher in females than in males. By contrast, CCP antibodies measured in individuals from the Dallas
Heart Study (middle panel) or in DRADR RA patients (right panel) did not show significant male-female differences.
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Group Age (yrs) ANA (EU) Female (%) AA (%) Hispanic (%)
HC High ANA (n = 18) 33.8 ± 3.4* 78.4 ± 10.0* 83 22 6
HC Low ANA (n = 16) 43.1 ± 3.7 7.0 ± 0.6 75 25 0
SLE (n = 14) 38.0 ± 4.0 182.4 ± 15.4 93 43 7
P** 0.2 0.001
# 0.4 0.4 0.6
*Values represent mean and standard error of the mean. **P-values were calculated by one-way ANOVA or Fisher’s exact test.
# Mean ANA in SLE was
significantly higher than in the High ANA HC group (P <0.05). ANA, antinuclear antibodies; SLE, systemic lupus erythematosus.
Figure 3 Heat map with clustering of IgM autoantibodies HC subjects and SLE patients. Clusters of study subjects are highlighted to
show groups of SLE patients (blue boxes) and ANA high HC (yellow ovals).
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Page 5 of 11(low ANA HC <High ANA HC <SLE) and to exclude any
with distributions that were highly skewed by one or two
individuals. This analysis yielded 14 IgGs; 9 of these with
the most significant P-values (Kruskal-Wallis test) are
shown (Figure 5). Four of the nine specificities are
directed against autoantigens found in skin tissues
(DSG4, MMP1, recombinant human collagen, integri-
na6b4) [8-10]. Others are associated with autoimmune
kidney disease (GBM), thyroid disorders (thyroglobulin),
scleroderma (PM/Scl100), and inflammatory arthritis
Figure 4 Heat map with clustering of IgG autoantibodies in HC subjects and SLE patients. Clusters of study subjects show groups of SLE
patients (blue boxes) and ANA high HC (yellow ovals).
Li et al. Arthritis Research & Therapy 2011, 13:R38
http://arthritis-research.com/content/13/2/R38
Page 6 of 11(proteoglycan) [11]. A search for autoantibodies that
might be associated with a lowered risk of lupus was car-
ried out by choosing specificities that were elevated in
high ANA HC but were not high in SLE patients. The
ratio of the mean values for the high ANA HC group to
the corresponding SLE group mean was calculated, and
three specificities had IgG ratios greater than 4.0: Jurkat
T cells, gliadin and SK-N-SH (Figure 6). In each of these,
a subset of the high ANA HC individuals showed strong
reactivity while SLE patients did not have high values.
For gliadin, an autoantigen associated with celiac disease,
and Jurkat, a measure of anti-T cell and thymocyte anti-
bodies, the distributions were significantly different for
the three groups (P = 0.042 and 0.033, respectively).
Although the antineuronal antibodies measured by
SKNSH reactivity did not show significant differences
across groups by ANOVA, a dichotomized analysis
showed values greater than 400 MFI units were present
only in the high ANA HC group (P = 0.0242). The four
highest values for each of these different autoantibodies
represented the same individuals.
An independent ELISA assay was carried out for thyr-
oglobulin (TG) autoantibodies to compare with the find-
ings on the array. Anti-TG levels of the IgG class
measured by the two techniques were significantly cor-
related (P = 0.007) and values were significantly higher
in the HC high ANA group (1.18 ± 0.23 EU) than the
HC low ANA group (0.60 ± 0.07 EU; P = 0.030), consis-
tent with the array results.
Gene expression profiles
Mean gene expression values were compared between
the two HC groups defined by ANA status, and this
analysis identified 95 dysregulated genes at a significance
level of P <0.01. Somewhat surprisingly, the vast major-
ity of these genes (90 out of 95) were upregulated in the
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Figure 5 IgG autoantibodies showing significant stepwise elevations in the three study groups. P-values calculated using Kruskall-Wallis test.
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gulated in the high ANA HC group, the highest (two-
fold difference) was TGM2, which encodes the celiac
disease autoantigen transglutaminase 2.
To detect specificities that might be informative of
ANA and diagnosis status, a second analysis was carried
out by first comparing the SLE and high ANA HC
groups to determine gene specificities that were signifi-
cantly different at a significance level of P <0.001. This
list was then sorted based on the values for the calcu-
lated ratio SLE/ANA-High HC. The most highly
expressed specificity in this list was IFI27,w h i c hw a s
65-fold higher in SLE than in ANA High HC. Overall,
69 genes in this list had greater than two-fold differ-
ences between SLE and ANA High HC. These 69 genes
were then resorted based on differences in the ratio of
ANA High HC/ANA Low HC. The highest ratio in this
set was two-fold and out of the top 10 specificities, 7
w e r ei nt h eT y p eIi n t e r f e r o ns i g n a t u r e( IFITM3, MX1,
IFI6, IFI44L, ISG15, OAS1, IFIT3) and one encodes a
protein that is activated by dsRNA as might be present
in a viral infection (EIF2AK2). The specificities that
most clearly showed stepwise increases in the three
groups going from Low ANA HC to High ANA HC to
SLE were IFITM3 and MX-1 (Figure 7).
Discussion
Detecting autoimmune disease in early or preclinical
stages is clinically important because the institution of
treatment prior to the onset of organ damage has a
greater chance to ameliorate or even cure the disease
[12]. However, early and reliable diagnosis of lupus is a
challenge, in large part due to the performance profiles
of available diagnostic tests. The optimal test would be
sensitive enough to detect all individuals who have a
disease while at the same time delivering sufficient spe-
cificity to have reasonable predictive probability that the
disease is likely. The classic screening test for SLE is the
presence in serum of antinuclear antibodies (ANAs)
measured by immunofluorescence staining of a cellular
substrate [13]. ANA positivity is for all practical pur-
poses required to make a diagnosis of lupus since more
than 99% of patients with SLE have significant levels of
this autoantibody detected at some time during the
course of disease. However, since the prevalence of SLE
is low, most individuals presenting to a physician with
ANA positivity do not in fact have lupus and are not at
high risk for developing this disease. But there are few
available quantitative and objective measures to establish
prognosis for an individual with a positive ANA. This
contrasts to the tools that are available for determining
the risk of cardiovascular disease, where multifaceted
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Figure 6 IgG autoantibodies with elevated levels in high ANA HCs but not in SLE patients. IgM reactivity for these same three
autoantigens had similar patterns (not shown).
Figure 7 Expression of Type I IFN signature genes in the three
study groups. A stepwise pattern of increase is observed for
IFITM3, MX1 and IFIT3. The genes IFI44L and IFI27 show increases
that are relatively specific for SLE. Other IFN genes without elevation
in the high ANA HC group shown with black symbols are: IFI6,
HES4, ISG15, OAS1, IFIT3, HERC5, EIF2AK2.
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tory, social habits, body measurements and lab tests can
generate a reasonable and very personalized risk predic-
tion for an individual patient [14].
In practice, physicians actually do employ some profil-
ing to assess the risk associated with ANA positivity.
Young women are more likely to develop lupus than old
men, for example, so ANA positivity in the former is of
greater concern. The present study confirms our pre-
vious observation that female gender is a risk factor for
significant ANA positivity [1]. This result is also consis-
tent with other findings in healthy control populations
including a study of 500 normal individuals in Brazil
showing that ANA positivity was almost twice as preva-
lent in females as in males [15]. Similar findings were
reported in a rural Canadian population, with the gen-
der difference being greatest at higher ANA levels, as
was also noted in the present study [16]. The enhanced
female risk profile does not appear to extend to the
anti-CCP antibody that is associated with RA, another
female-predominant autoimmune disorder. Reasons for
the association of female gender with strong ANA posi-
tivity remain obscure.
Age was not correlated with ANA levels in HCs,
which seems to contradict the generally-accepted
hypothesis that immunosenescence is associated with
increased autoantibody production due to decreased
self-regulatory mechanisms. The present findings are
consistent, however, with other reports [15] and suggest
that in a cross-sectional analysis such as this there are
many reasons for ANA positivity. The younger indivi-
duals may in fact have abnormal immune regulation
that predisposes to SLE-like disease while older persons
may develop autoreactivity as part of aging immune
responses that do not lead to development of pathology.
Other clues are available to suggest approaches to
stratifying risk in the ANA-positive population. One is
the well-recognized presence of other autoantibodies
that accumulate prior to SLE diagnosis [4]. The preva-
lence of any one of these is low, however. For example,
ribosomal P autoantibodies are highly specific for SLE
but are present in less than one-third of patients [17].
This finding predicts that if autoantibodies are included
in risk profiling, multiplexed assays will be required.
One such approach that is available clinically, the ENA
panel, was not useful in the high ANA HC individuals
in the present study because very few positives were
found. This result is consistent with our previous
experience indicating that only the high ANA positives
are likely to have ENA specificities [1] and even then,
the prevalence of other autoantibodies in HCs is very
low. The alternative approach which has been applied in
the present study is to greatly expand the repertoire of
autoantibodies that can be probed by use of an
autoantigen array, which in other studies has been
shown to provide novel insights into expressed autoanti-
body repertoires [18]. The array data in the present
study revealed increased autoreactivity in a group of
high ANA HCs. One of the elevated autoantibodies was
thyroglobulin, and since autoimmune thyroid disease is
probably about 10-fold more common than SLE [19],
this result suggests that a significant proportion of the
ANA positivity seen by rheumatologists is related to
thyroid autoimmunity. Longitudinal studies suggest that
thyroid autoreactivity, especially in women, may be pre-
dictive of thyroid dysfunction [20]. Autoantibodies to
cartilage proteoglycan can be measured in several sys-
temic and joint-specific rheumatic diseases including
Sjogren’s Syndrome, rheumatoid arthritis, lupus and
ankylosing spondylitis [21], suggesting that undetected
or preclinical joint inflammation may contribute to
ANA positivity. The relative increase in skin autoreactiv-
ity in the high ANA HC group might be related to a
relative enrichment for skin antigens on the arrays, so
this finding should be interpreted with caution. How-
ever, it does raise the interesting question of whether
some early autoimmune events might take place in cuta-
neous structures. Transient ANA positivity has been
observed in patients with polymorphous light eruption
[22] and exposure to sun in susceptible individuals can
trigger major organ-damaging lupus [23]. The interface
dermatitis that characterizes the pathology in SLE as
well as in other skin disorders may precede a diagnosis
of lupus [24] and is associated with activation of the
Type I interferon gene signature [25]. The triggering of
this set of genes in skin, however, is not limited to
inflammatory disease but can also occur as part of the
immune response to viruses, raising the question of
whether cutaneous reactions to environmental agents in
susceptible hosts might generalize to a systemic
response.
The autoantibody arrays show that although the auto-
reactivity spectrum in SLE is broad, not all specificities
are elevated. Upregulated autoantibodies to gliadin, and
to T lymphocytes and neuroblastoma cells were present
only in the ANA high HC group, and not in the SLE
patients. This result confirms in part our previous report
that gliadin autoreactivity is associated with incomplete
forms of lupus that are associated with myopathies [26].
Whether these autoantibodies are actively protective and
lower the risk of lupus or alternatively are predictive of
other autoimmune diseases developing in these indivi-
duals will require further longitudinal investigation.
Upregulated genes observed in high ANA HC indivi-
duals include some in the Type I IFN signature that are
associated with SLE [27,28]. While some of these genes,
notably IFI27, were only elevated in SLE, others such as
MX-1 showed an intermediate level in the High ANA
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lated of the IFN genes in our sample, other data suggest
that IFI27 is relatively more specific for lupus than at
least some of the other IFN-inducible genes. A recent
study demonstrated that IFI27 is more likely to be upre-
gulated in lupus than in another autoimmune condition,
idiopathic thrombocytopenic purpura [29]. The specific
functions of many of the proteins associated with IFN-
related genes are obscure, but MX-1 is closely associated
with the response to the influenza virus, so upregulation
of this gene in normal individuals might reflect the ubi-
quitous exposure to this pathogen.
The present data suggest possible components of a
lupus risk profile. As in the cardiovascular risk profiling
equations, gender will be a factor but in lupus the risk
will be associated with females rather than males. The
age category will be inverted from that of cardiovascular
disease, with greater weight given to younger ages. The
lupus risk is correlated with ANA levels, not just posi-
tivity, with values in the upper quartile having a two- to
three-fold elevation of risk [1], so this will be an impor-
tant component. Other autoantibodies that may add to
risk include those that are clinically well-known like
anti-dsDNA and anti-Sm, as well as other novel specifi-
cities including the skin determinants identified in the
present study. On the other hand, antineuronal, anti-
thyroid or gliadin autoantibodies might steer attention
away from SLE towards other autoimmune disorders.
Elevated expression of genes related to the Type I IFN
signature is likely to add points to the risk equation.
This study has several limitations. One is the lack of
information regarding use of medications, especially
hormones, by the HC. Whether administration of estro-
gen in the form of oral contraceptives or postmenopau-
sal replacement therapy might induce high ANA levels
in a healthy individual cannot be ascertained from our
data. Another limitation is the cross-sectional design
which does not permit insights into changes that evolve
over time. And it would be of interest to determine
reactivity to foreign antigens such as infectious agents to
further interpret the significance of the autoreactive
responses. Ultimately, validation of risk profiles will
require longitudinal studies.
Finally, since SLE is a relatively rare disorder, the
probability of finding a new onset patient is low even
after ANA positivity has been identified. One approach
to increasing the likelihood of useful results would be to
follow individuals who already have some of the identi-
fied risk profile components. For example, studies could
be carried out in individuals who have been sent for
ANA testing for any reason. The very fact that the indi-
vidual sought medical attention and that an ANA was
ordered is likely to increase the pre-test probability of
disease. Such an approach has shown that in the
population of individuals sent for rheumatoid factor
testing, the pre-test probability for RA is 17% [30].
Conclusions
T h i ss t u d ys h o w st h a ti tm a yb ep o s s i b l et oi d e n t i f yt h e
small percentage of ANA positive individuals who are
at risk for development of SLE. Characterization of
protein and gene expression profiles accompanying
ANA positivity has potential to enable more precise
risk quantification and ultimately to identify pre-
clinical stages of this disease that would allow early
and definitive treatment.
Additional material
Additional file 1: Components of the Autoantigen Array. This table
lists the components of the array along with sources of the
autoantigens.
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